Mak Koon-Hou, Lee Lai-Heng, Wong Aaron, Chan Charles, Koh Tian-Hai, Lau Kean-Wah, Lim Yean-Leng
Department of Cardiology, National Heart Centre, Singapore.
Am J Cardiol. 2002 Apr 15;89(8):930-6. doi: 10.1016/s0002-9149(02)02241-5.
The purpose of this study was to determine the impact of these 2 reperfusion strategies (reduced-dose alteplase plus abciximab or direct angioplasty plus abciximab) on fibrinolytic and thrombin generation activities. The effect of reduced-dose alteplase plus abciximab and direct angioplasty plus abciximab on hemostatic factors is unknown. Of 70 patients with acute myocardial infarction of < or = 6 hours, 34 were randomized to reduced-dose alteplase (35 to 50 mg in 1 hour) and 36 to direct angioplasty. A standard bolus and infusion dose of abciximab was administered to all patients. Blood specimens were collected at baseline, and at 1, 4, 12, and 24 hours. The following parameters were assayed: fibrinogen, plasminogen and antiplasmin activities, tissue plasminogen activator antigen, D-dimer, prothrombin fragments F1 + 2, and thrombin/antithrombin III complexes. Among patients treated with reduced-dose alteplase plus abciximab, the fibrinogen level decreased by 28.4% in the first hour (11.7 +/- 3.4 vs 7.8 +/- 2.5 micromol/L, p <0.001). Correspondingly, plasminogen and antiplasmin activities decreased by 43.8% (p <0.001) and 59.1% (p <0.001), respectively. Prothrombin fragments F1 + 2 increased from 2.2 +/- 1.7 to 4.2 +/- 1.6 nmol/L (1 hour) (p <0.001) and thrombin/antithrombin III increased from 16.3 +/- 15.0 to 33.5 +/- 19.9 microg/L (1 hour) (p <0.001). Conversely, in the direct angioplasty group, there was a marginal elevation in fibrinogen level at 1 hour (10.2 +/- 2.4 vs 10.6 +/- 2.0 micromol/L, p = 0.064) despite a significant reduction in plasminogen and an increase in tissue plasminogen activator levels. There was no significant change in prothrombin fragments F1 + 2 and thrombin/antithrombin III levels. Thus, there was considerable fibrinolytic activity with reduced-dose alteplase plus abciximab; thrombin generation was not prevented. Among patients treated with direct angioplasty, there was some endogenous fibrinolytic activity, but there was no significant thrombin generation.
本研究的目的是确定这两种再灌注策略(减量阿替普酶加阿昔单抗或直接血管成形术加阿昔单抗)对纤溶和凝血酶生成活性的影响。减量阿替普酶加阿昔单抗和直接血管成形术加阿昔单抗对止血因子的影响尚不清楚。在70例急性心肌梗死发病时间≤6小时的患者中,34例被随机分配接受减量阿替普酶(1小时内35至50毫克)治疗,36例接受直接血管成形术治疗。所有患者均给予标准剂量的阿昔单抗推注和输注。在基线、1小时、4小时、12小时和24小时采集血样。检测以下参数:纤维蛋白原、纤溶酶原和抗纤溶酶活性、组织纤溶酶原激活物抗原、D - 二聚体、凝血酶原片段F1 + 2以及凝血酶/抗凝血酶III复合物。在接受减量阿替普酶加阿昔单抗治疗的患者中,纤维蛋白原水平在第1小时下降了28.4%(11.7±3.4 vs 7.8±2.5微摩尔/升,p<0.001)。相应地,纤溶酶原和抗纤溶酶活性分别下降了43.8%(p<0.001)和59.1%(p<0.001)。凝血酶原片段F1 + 2从2.2±1.7纳摩尔/升增至4.2±1.6纳摩尔/升(1小时)(p<0.001),凝血酶/抗凝血酶III从16.3±15.0微克/升增至33.5±19.9微克/升(1小时)(p<0.001)。相反,在直接血管成形术组,尽管纤溶酶原显著减少且组织纤溶酶原激活物水平升高,但纤维蛋白原水平在1小时时有轻微升高(10.2±2.4 vs 10.6±2.0微摩尔/升,p = 0.064)。凝血酶原片段F1 + 2和凝血酶/抗凝血酶III水平无显著变化。因此,减量阿替普酶加阿昔单抗具有相当大的纤溶活性;未防止凝血酶生成。在接受直接血管成形术治疗的患者中,存在一些内源性纤溶活性,但无显著的凝血酶生成。